NXL
Nexalin Technology, Inc.0.8115
-0.0085-1.04%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
15.14MP/E (TTM)
-Basic EPS (TTM)
-0.65Dividend Yield
0%Recent Filings
8-K
Pivotal insomnia trial advances
Nexalin advanced its pivotal clinical trial for the HALO™ Clarity device targeting moderate to severe insomnia, announced February 24, 2026, in collaboration with Lindus Health. This 150-patient, triple-blinded, sham-controlled decentralized study supports a planned de novo FDA submission. Trial builds on prior positive data. Execution risks loom large.
8-K
Nasdaq bid price deficiency
Nexalin Technology received a Nasdaq notice on January 21, 2026, for failing the $1.00 minimum bid price over 30 consecutive business days, under Listing Rule 5550(a)(2). Listing remains intact, with 180 days until July 20, 2026, to hit $1.00 for 10 straight trading days. No reverse split planned. Delisting risks OTC trading.
8-K
Nexalin updates investor deck
Nexalin Technology released an updated investor presentation on December 5, 2025, spotlighting its high-power 15mA neurostimulation tech as a drug-free fix for mental health woes like depression and insomnia. It slams drugs for low efficacy, side effects, and addiction while calling out rivals' weak 1-1.5mA limits. Targets $60B market. No financials disclosed.
10-Q
Q3 FY2025 results
Nexalin's Q3 revenue fell 50% y/y to $18K while gross margin expanded to 78% from 65%, yet operating loss narrowed 6% to $(2.35)M on lower SG&A. Nine-month revenue dipped 8% y/y to $130K, with gross margin contracting to 68% from 79%; operating loss widened 23% to $(5.98)M (derived), driven by 89% higher R&D on Halo and clinical trials, offset somewhat by $133K other income. Cash burned $3.8M on operations; equity raises added $4.6M, leaving $0.6M cash plus $3.8M short-term investments against no debt. FDA accepted Q-Sub for Gen-2 SYNC in Alzheimer's. Warrants expired September 2025. Ongoing U.S. trade tariffs threaten imports.
8-K
Nexalin boosts ATM offering to $10M
Nexalin Technology expanded its at-the-market offering program on October 15, 2025, boosting the maximum sales value from $3.1 million to $10 million through an amendment with Maxim Group LLC. This ups the available shares for issuance to about $4.3 million as of the date. The move enhances funding flexibility amid ongoing operations. Yet risks linger in market volatility.
AMIX
Autonomix Medical, Inc.
0.63-0.03
BWAY
Brainsway Ltd.
16.87-0.47
CBLL
CeriBell, Inc.
21.99+0.09
HSDT
Solana Company
3.10+0.06
INSP
Inspire Medical Systems, Inc.
115.51-3.75
LIVN
LivaNova PLC
63.08+0.02
NMTC
NeuroOne Medical Technologies C
0.71+0.05
NPCE
Neuropace, Inc.
15.88-0.04
RMSL
RemSleep Holdings, Inc.
0.00+0.00
STIM
Neuronetics, Inc.
1.65-0.11